https://www.selleckchem.com/pr....oducts/NVP-AUY922.ht
Purpose To model Medicare Part B and patient savings associated with increased bevacizumab payment and utilization for intravitreal anti-vascular endothelial growth factor (VEGF) therapy. Design Cost analysis. Methods Medicare claims and IRIS® Registry data were used to calculate Medicare Part B expenditures and patient co-pays for anti-VEGF agents with increasing reimbursement and utilization of bevacizumab relative to ranibizumab and aflibercept. Main outcome measures Medicare Part B costs and patient co-pays for anti-VEGF agents i
Respect!
Kommentar
Delen
